OmniaBio Revenue and Competitors
Estimated Revenue & Valuation
- OmniaBio's estimated annual revenue is currently $31.2M per year.
- OmniaBio's estimated revenue per employee is $188,818
Employee Data
- OmniaBio has 165 Employees.
- OmniaBio grew their employee count by 59% last year.
OmniaBio's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Chief Legal Officer | Reveal Email/Phone |
3 | Chief Commercial Officer | Reveal Email/Phone |
4 | VP, Supply Chain | Reveal Email/Phone |
5 | Director, Business Development | Reveal Email/Phone |
6 | Director, Business Development | Reveal Email/Phone |
7 | Associate Director, MSAT | Reveal Email/Phone |
8 | Director Commercial Operations | Reveal Email/Phone |
9 | Associate Director | Reveal Email/Phone |
10 | Director, Business Development - Cell and Gene Therapy | Reveal Email/Phone |
OmniaBio Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $4.2M | 27 | 29% | $5M | N/A |
#2 | $1.7M | 11 | 22% | N/A | N/A |
#3 | $0.9M | 11 | -72% | $39.4M | N/A |
#4 | $1M | 13 | -84% | $23.8M | N/A |
#5 | $94.4M | 609 | 8% | N/A | N/A |
#6 | $3.4M | 22 | 10% | N/A | N/A |
#7 | $9.5M | 61 | -68% | N/A | N/A |
#8 | $18.1M | 117 | 30% | N/A | N/A |
#9 | $21.7M | 140 | -6% | N/A | N/A |
#10 | $1M | 13 | -41% | N/A | N/A |
What Is OmniaBio?
OmniaBio Inc., a subsidiary of CCRM, launched July 1, 2022. OmniaBio is a contract development and manufacturing organization (CDMO) conducting process development and producing gene-modified cells and viral vectors for Phase I clinical trials to commercial-scale manufacturing. OmniaBio is bringing life-saving cell and gene therapies to patients in Canada and around the world.
keywords:N/AN/A
Total Funding
165
Number of Employees
$31.2M
Revenue (est)
59%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $32.7M | 165 | 29% | N/A |
#2 | $49.3M | 166 | 13% | N/A |
#3 | $35M | 168 | -3% | N/A |
#4 | $27.9M | 169 | N/A | N/A |
#5 | $50.5M | 170 | 12% | N/A |